Abstract
You have accessJournal of UrologyCME1 May 2022V09-05 NOVEL TECHNIQUE FOR INJECTION OF LIPIODOL AS FIDUCIAL MARKER FOR RADIOTHERAPY TREATMENT IN BLADDER CANCER Aoife McVey, Elvira Polo Alonso, Olivia Fraser, Daryl Lim Joon, and Gregory Jack Aoife McVeyAoife McVey More articles by this author , Elvira Polo AlonsoElvira Polo Alonso More articles by this author , Olivia FraserOlivia Fraser More articles by this author , Daryl Lim JoonDaryl Lim Joon More articles by this author , and Gregory JackGregory Jack More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002617.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Radiotherapy for the primary treatment of bladder cancer is becoming increasingly common. Several studies have shown that fiducial marking of the site of the primary tumour can assist with radiotherapy planning and reduce dosimetry to surrounding benign bladder tissue. Lipiodol, which is Iodinated contrast agent can be injected cystoscopically and serve as a fiducial marker to demarcate the primary bladder tagets for radiotherapy. Few studies have looked at the ideal technique and dose of lipiodol injection. Furthermore those study is typically advise 5 mL of concentrated lipiodol injected in 1mL aliquats through a rigid cystoscope with a williams cystoscopic needle, which tends to lead to excessive urothelial migration of the lipiodol. We described a novel technique of 100uL injections of 1:3 dilute lipiodol performed via flexible cystoscopy under local anaesthesia. METHODS: After obtaining patient consent, we video-recorded a case of cystoscopic injection of Lipiodol in a patient selected for image guided radiotherapy treatment (IGRT). Using iMovie editing software we prepared a video describing this technique. RESULTS: This technique for injection has been successfully implemented at our single centre and has allowed effective delivery of targeted radiotherapy treatment using Lipiodol as a fiducial marker. CONCLUSIONS: This is a simple, reproducible, and easily performed office procedure with durable results and minimal lipiodol migration. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e806 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Aoife McVey More articles by this author Elvira Polo Alonso More articles by this author Olivia Fraser More articles by this author Daryl Lim Joon More articles by this author Gregory Jack More articles by this author Expand All Advertisement PDF DownloadLoading ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.